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Abstract
Background: Prevalence of stage 3 chronic kidney disease (CKD) is increasing according to the NHANES study. 
Prevalence has been calculated using the MDRD study equation for estimating glomerular filtration rate (GFR). 
Recently, a new estimator based on creatinine, the CKD-EPI equation, has been proposed which is presumed to better 
perform in normal GFR ranges. The aim of the study was to measure the difference in prevalence of stage 3 CKD in a 
population using either the MDRD or the CKD-EPI study equations.
Methods: CKD screening is organized in the Province of Liège, Belgium. On a voluntary basis, people aged between 45 
and 75 years are invited to be screened. GFR is estimated by the MDRD study equation and by the "new" CKD-EPI 
equations.
Results: The population screened consisted in 1992 people (47% of men). Mean serum creatinine was 0.86 ± 0.20 mg/
dL. The prevalence of stage 3 CKD in this population using the MDRD or the CKD-EPI equations was 11.04 and 7.98%, 
respectively. The prevalence of stage 3 CKD is significantly higher with the MDRD study equation (p < 0,0012).
Conclusions: Prevalence of stage 3 CKD varies strongly following the method used for estimating GFR, MDRD or CKD-
EPI study equations. Such discrepancies are of importance and must be confirmed and explained by additional studies 
using GFR measured with a reference method.
Background
Prevalence of end-stage renal failure is increasing in
Western Countries [1] even if this fact has been recently
questioned [2]. In this context, prevention of chronic kid-
ney disease (CKD) is of importance [3]. The first step for
efficient prevention is an early diagnosis. However, serum
creatinine is of limited value for such a task, as it is classi-
cally known that creatinine will rise over normal values
only when 50% of glomerular filtration rate (GFR) have
already been lost [4,5]. This creatinine lack of sensitivity
is especially due to its relationship with muscular mass
and will be noted particularly in population with lower
muscular mass, notably the older population [4,6]. Sev-
eral authors have proposed creatinine-based equation to
improve GFR estimation. The MDRD study equation is
one of the most used for this purpose [7]. So, epidemio-
logical data have shown that nearly 10% of the population
in the USA has stage 3 CKD or worse, defined as esti-
mated GFR lower than 60 mL/min/1.73 m2  with the
MDRD study equation [1]. However, we and others have
u n d e r l i n e d  t h a t  M D R D  e q u a t i o n  i s  n o t  a c c u r a t e  a n d
especially not precise for the estimation of GFR in healthy
population and, more obviously, when it is applied to nor-
mal creatinine values [2,8,9]. There are several good rea-
sons to believe that MDRD study equation
underestimates GFR (and thus overestimate CKD preva-
lence) in these populations with normal or near-normal
creatinine values [2,10,11].
According to these limitations, Levey's group who is
already at the origin of the MDRD study equation has
built a new creatinine-based equation from a large sam-
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ple of CKD and healthy subjects. This CKD-EPI study
equation includes, in fact, four different equations follow-
ing the sex and the ethnicity (Table 1) [12]. It seems thus
interesting to evaluate the prevalence of CKD (defined as
estimated GFR under 60 ml/min/1.73 m2) with the
MDRD study equation on one hand and with the CKD-
EPI equation on the other hand.
Methods
This study has been approved by the Ethic Committee of
our University Hospital. The Belgian number study is
B70720071509. This prospective study was driven in the
context of the CKD screening program organized by the
Province of Liège's Health deputation. Province of Liège
is one of the ten provinces in Belgium. Its area is 3862
km2 and its population from 2005 data has been calcu-
lated to reach a total of 1.037.161 inhabitants. The CKD
screening is organized by a medical bus that travels
through the 84 communes of that Province. On a volun-
tary basis, people aged over 45 years are invited to be
screened. All patients have been informed and have
signed informed consent. Data have been anonymously
analyzed. Blood samples and anthropometrical data are
collected and a short interview is done. Between June
2008 and April 2009, frozen blood samples were sent to
the Clinical Chemistry laboratory of the University of
Liège where they were immediately thawed and assayed.
Serum creatinine was measured by the IDMS traceable
Jaffé method from Roche (compensated Jaffé, Roche
Diagnostics, Mannheim, Germany) on Modular [13,14].
Our university laboratory is currently accredited against
the ISO 15189 Standard. As our creatinine is IDMS trace-
able, the new "175" MDRD study equation was used [7].
All results are expressed as mean ± SD. We have calcu-
lated and compared the percentage of patients with stage
3 CKD or worse obtained with the two equations, but
also the coefficients of correlation between the different
equations. Agreement between equations to discriminate
GFR over and less than 60 mL/min/1.73 m2 has been
evaluated by Kappa statistics.
The results of GFR estimated by the MDRD study and
the CKD-EPI equations have also been compared by
Bland and Altman analysis [15]. In these analyses, we
have arbitrarily chosen the MDRD study equation results
as the referent. Bias between equations was defined as the
mean of the differences. The SD around the mean
reflected the dispersion and the precision of the equa-
tions. P < 0.05 was considered as significant. We have also
evaluated if difference between equations might be corre-
lated to variables such as age, sex, creatinine or estimated
GFR levels. We also repeated Bland and Altman analysis
in subgroups according to sex and level of estimated GFR
(over or below 60 ml/min/1.73 m2). All analyses were per-
formed using MedCalc® (MedCalc Software, Mariakerke,
Belgium).
Results
During the study period, 1992 people were screened (47%
male and 53% women). Anthropometric, clinical and bio-
logical characteristics of the global population are shown
in Table 2. By paired samples t-test, the estimated GFR by
the MDRD and the CKD-EPI study equations were differ-
ent from each other (p < 0.0001). Prevalence of stage 3
CKD when GFR was estimated by the MDRD equation
study was 11.04% (n = 220). This prevalence was signifi-
cantly and strongly higher than the prevalence obtained
when the CKD-EPI study equation which was 7.98% (n =
159)(p = 0.0012). However, Kappa statistics showed very
good agreement between the two equations (κ = 0.82).
Results given by the two equations were highly corre-
lated (p < 0.0001)(r = 0,93).
The Bland and Altman analysis results are summarized
in Figure 1. The mean difference between the MDRD
study and the CKD-EPI equation was -2.6 ± 7 mL/min/
1.73 m2.
By multinear regression analysis, difference between
MDRD and CKD-EPI results was dependent upon age
(the greater the age, the greater the difference, r = 0.4, p <
0.0001) and creatinine concentration (the lower the crea-
tinine, the greater the difference, r = -0.2, p < 0.0001).
Two subgroups analyses were conducted following sex
and estimated GFR. If we restricted analysis to estimated
GFR under 60 mL/min/1.73 m2 (with the MDRD study
equation)(n = 220), the paired samples t-test still showed
significant difference between the estimated GFR by the
MDRD and the CKD-EPI study equations (p < 0.0001).
Of course, this is still the case when results over 60 mL/
Table 1: Creatinine- (SCr; mg/dL) based equations for 
glomerular filtration rate (GFR) estimation.
4-variable MDRD Study equation
GFR (mL/min/1.73 m2) = 175 × SCr -1.154 × Age -0.203 × 0.742 (if 
woman) × 1.21 (if black)
CKD-EPI Study equation (white subjects)
If woman:
if creatinine < 0.7 mg/dL:
GFR (mL/min/1.73 m2) = 144 × SCr/0.7 -0.329 × 0.993age
if creatinine > 0.7 mg/dL:
GFR (mL/min/1.73 m2) = 144 × SCr/0.7 -1.209 × 0.993age
If man:
if creatinine < 0.9 mg/dL:
GFR (mL/min/1.73 m2) = 141 × SCr/0.9 -0.411 × 0.993age
if creatinine > 0.9 mg/dL:
GFR (mL/min/1.73 m2) = 141 × SCr/0.9 -1.209 × 0.993ageDelanaye et al. BMC Nephrology 2010, 11:8
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min/1.73 m2 were analyzed (n = 1772). The results of the
Bland and Altman analyses were more interesting.
Indeed, the mean difference between the MDRD study
and the CKD-EPI equation was -2.3 ± 1.9 mL/min/1.73
m2 and -2.7 ± 7.4 mL/min/1.73 m2 when analysis con-
cerned estimated GFR under and over 60 mL/min/1.73
m2, respectively. If the bias was equivalent in these two
subgroups, deviation around the bias was significantly
lower in the subgroup with estimated GFR less than 60
mL/min/1.73 m2 compared to global population or the
subgroup with GFR higher than 60 mL/min/1.73 m2 (F-
test, p < 0,001).
Anthropometrical and biological values were different
between men and women, as it was illustrated in Table 3.
Only, the mean results of the CKD-EPI equations were
not different between men and women. Kappa statistics
showed very good agreement between the two equations
but agreement seemed slightly better for men than for
women (κ = 0.92 and 0.76, respectively). The mean differ-
ence between the MDRD study and the CKD-EPI equa-
tion was -0.8 ± 7 mL/min/1.73 m2 and -4.4 ± 6.5 mL/min/
1.73 m2  when analysis concerned men and women,
respectively. The difference between these last results
was highly significant (p < 0.0001). In the same way, prev-
alence of stage 3 CKD in men was 8.47% and 7.29% with
the MDRD and the CKD-EPI equations, respectively
(non significant difference). I n  w o m e n ,  p r e v a l e n c e  o f
stage 3 CKD was highly different using either the MDRD
or the CKD-EPI equations (13.31% versus  8.59%, p =
0.0007).
Discussion
Epidemiologic studies in different Western countries
have recently shown that prevalence of CKD, defined as
GFR under 60 mL/min/1.73 m2, is about 10% in the global
population [1,16]. These data have been obtained with
the MDRD study equation using a well calibrated serum
creatinine [17,18]. However, the use of this equation is
not free from criticisms. We, and others, have demon-
strated that this equation tends to strongly underestimate
GFR in healthy populations and, more generally, in
patients with normal or near normal creatinine values
[2,10,11,19]. Admitting this fact, the Levey's group has
recently proposed a new equation which is thought to be
especially better in the higher GFR range (over 60 ml/
min/1.73 m2). In this view, the new CKD-EPI equations
are different following the creatinine value (0.7 mg/dL for
the women and 0.9 mg/dL for the men). This adaptation
seems logical as relationship between GFR and creatinine
is different in healthy as compared to CKD subjects. The
b e t t e r  a c c u r a c y  o f  t h e  n e w  e q u a t i o n  i s  a l s o  c e r t a i n l y
explained by the authors because the inclusion of healthy
subjects in the equations development study (13% i.e. 694
healthy kidney donors). Logically, using the new CKD-
EPI equations, the prevalence of stage 3 CKD in our pop-
ulation is significantly lower than if the MDRD study
equation is used (7.98% versus  11.04%). Over 1992
patients screened, 61 (3.06%) were classified as having
stage 3 CKD with the MDRD study equation compared to
the CKD-EPI study equation. These data are not negligi-
ble from an epidemiological point of view.
Differences between MDRD and CKD-EPI equations
are especially larger for the highest estimated GFR values.
If we arbitrary fix a limit of 60 ml/min/1.73 m2 estimated
by the MDRD study equations, differences between the
two equations are significantly higher for the values over
than below 60 ml/min/1.73 m2 (-2.3 ± 1.9 versus -2.7 ± 7.4
ml/min/1.73 m2, respectively). These differences are logi-
Table 2: Anthropometrical and biological description of the population (n = 1992).
N = 1992 Mean SD Range
Age (years) 62 8 45-84
Weight (Kg) 75 16 37-156
Height (cm) 167 9 140-196
BMI (Kg/m2)2 7 5 1 5 - 6 0
Creatinine (mg/dL) 0.86 0.2 0,4-2,7
MDRD study (mL/min/1.73 m2) 82 18 18-166
CKD-EPI study (mL/min/1.73 m2) 84 16 18-123
Data are expressed as mean ± SD.Delanaye et al. BMC Nephrology 2010, 11:8
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cal according to differences between equations. More
astonishing is the difference observed in subgroup analy-
sis according to gender. The difference between the two
equations seems more impressive in women than in men.
This is not explained by the GFR level or age as women
have higher mean GFR and are younger (see below for the
age effect). This difference could be explained by the
lower cut-off chosen in women for the CKD-EPI equa-
tions. As relationship between creatinine and GFR is
exponential, it could be logical that consequences on dif-
ference results between the two equations are more
important in women. Nevertheless, more studies in the
future are needed to explain such discrepancies between
estimators regarding to gender because, obviously, one of
the two equations is especially inaccurate in women.
In their presenting CKD-EPI article, Levey et al have
also compared prevalence of CKD in the NHANES study.
If we consider the same definition of stage 3 CKD, these
authors have found that prevalence of CKD in the
NHANES study was 9.88% with the CKD-EPI equation
and 10.82% with the MDRD study equations (Appendix
Table 6 in [12]). Difference in prevalence is more impres-
sive in our own study. One explanation could be the
higher mean age in our population. Indeed, one major
difference between the two equations is the "age factor".
In the MDRD study equation, a constant exponent is
applied to age (age-0.203) whereas age is an exponent in the
CKD-EPI equation (0.993age). Indeed, we find a signifi-
cant correlation between age and difference between
MDRD and CKD-EPI results (regression coefficient of
0.39 in multiple regression analysis). However, even if the
MDRD study equation's performance in older population
remains controversial [20,21], the performance of the
CKD-EPI equation in patients or subjects over 70 years
old has not been studied (only 3% of patients between 70
and 75 years old in development data of the CKD-EPI
Figure 1 Bland and Altman analysis between the MDRD study equation and the new CKD-EPI equations. The continuous line represents the 
mean difference between estimated GFRs, whereas the dashed lines represent the limits of agreement (mean difference ± 2SD). All values are ex-
pressed in mL/min/1.73 m2.
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equations study). Discrepancy between our results and
NHANES study results could also be the result of poten-
tial anthropometrical differences between American and
European populations.
The new CKD-EPI equation is certainly interesting and
its performance will probably be better than the MDRD
study equation in population free from renal disease. Yet,
some limitations may be advanced. Firstly, the choice of
the creatinine cut-off is logically different according to
sex (0.9 mg/dL for men and 0.7 mg/dL for women). How-
ever, it would be also logical that equations vary with age
as relationship between creatinine levels is also strongly
influenced by age [4]. Secondly, we underline, once again,
the lack of data regarding older patients (more than 70
years old) that are clearly underrepresented in the CKD-
EPI study. Thirdly, we have recently criticized the way the
new "IDMS" traceable MDRD and more precisely the fac-
tor 175 has been obtained to make results IDMS trace-
able [9,10]. This criticism is also valid for the CKD-EPI
equation because serum creatinine measurements from
the development data are coming from studies (MDRD
and AASK for example) where creatinine had been mea-
sured with Jaffé methods. So, from our point of view, the
factors used in the CKD-EPI equations (144 for women
and 141 for men) are too low inducing a systematic over-
estimation of CKD prevalence. Lastly, the major criticism
for the new CKD-EPI equations is its lack of advantage
regarding its precision in estimating GFR. Indeed, in the
Levey study, if for subjects with GFR over 60 ml/min/1.73
m2, the bias with measured GFR is improved when using
the CKD-EPI equations as compared to the MDRD equa-
tion (median difference of 3.5 versus 10.6 mL/min/1.73
m2), however, the precision of the CKD-EPI equation in
the same range of GFR doesn't appear better (and even
seems slightly worse) than those of the MDRD (precision
is reflected by interquartile range for differences: 25.7
versus 24.2 mL/min/1.73 m2, respectively) [12]. So, if GFR
estimation by CKD-EPI equation has an improved sys-
tematic bias and accuracy, this equation does not
improve the precision of the estimation. This is disap-
pointing but not astonishing as bias is, by nature, system-
atic although precision is random and especially linked to
the precision of the creatinine measurement. The latter is
not improved in the CKD-EPI equation in comparison
with the MDRD equation (as already mentioned, creati-
nine has been measured with Jaffé methods) [8,9].
There are some limitations to our study. First, the main
limitation is linked to the fact that we have not measured
GFR with a reference method. So, even if we have indirect
arguments to affirm that MDRD study equations overes-
t i m a t e  CKD  p r ev a l e n c e  i n  g l o b a l  po p u l a t i o n s,  s u c h  a n
assertion can only be checked if a reference method GFR
is used. Our data only underline potential strong discrep-
ancies between results in epidemiological studies when
either the MDRD or the CKD-EPI study equations are
used. Epidemiological studies on renal function in the
global population are still urgently waited but it repre-
sents heavy work. Second, our stage 3 CKD prevalence
data are of interest only because they illustrate these dis-
crepancies. As our population is clearly not representa-
tive of the Belgian population (because only volunteers
are included), our stage 3 CKD prevalence results must
not be considered for epidemiological considerations. For
this reason, data regarding proteinuria or hypertension
status that are lacking in this study are of relatively poor
interest in our study. Third, we have no data on the eth-
Table 3: Anthropometrical and biological description of the population according to gender.
Men (n = 933) Women (n = 1059) Difference
Age (years) 62 ± 8 61 ± 8 P = 0.0054
Weight (Kg) 83 ± 15 68 ± 13 P < 0.001
Height (cm) 174 ± 7 161 ± 6 P < 0.001
BMI (Kg/m2) 27 ± 5 26 ± 5 P < 0.001
Creatinine (mg/dL) 0.95 ± 0.2 0.78 ± 0.18 P < 0.001
MDRD study (mL/min/1.73 m2) 84 ± 18 79 ± 18 P < 0.001
CKD-EPI study
(mL/min/1.73 m2)
85 ± 15 84 ± 16 NS
Data are expressed as mean ± SD.Delanaye et al. BMC Nephrology 2010, 11:8
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nicity. As the ethnicity factor varies following the equa-
tions, this could be source of bias. However, in Belgium,
C a u c a s i a n s  a r e ,  f r o m  f a r ,  t h e  d o m i n a n t  e t h n i c  g r o u p .
Moreover, there is little doubt that differences observed
in our study are not due to the ethnic factor (1.21 in the
MDRD study equation and 1.16 in the CKD-EPI equa-
tions). Four, like in several epidemiological studies, our
subjects have been tested only once, although definition
of CKD sensu stricto implies that two or three testing
have been undertaken over a three months period. Last,
we have defined CKD as GFR less than 60 mL/min/1.73
m2. The definition of CKD is however subject of debate,
notably in elderly population [2,22]. Whatever, our data
do not permit to bring to close this debate.
Conclusions
The present study has illustrated large discrepancies
observed in the prevalence of stage 3 CKD in a popula-
tion according to the method used for estimating GFR.
These differences seem especially relevant in women,
older and subjects with estimated GFR over 60 ml/min/
1.73 m2. We have argument to disfavour MDRD study
equations in epidemiological studies but it must not be
concluded that the CKD-EPI equations is absolutely free
from criticisms. For example, we have recently illustrated
discrepancies in CKD prevalence using either the MDRD
and the cystatin C-based equations [8,23]. We have also
strong discrepancies between CKD prevalence using
either CKD-EPI or the cystatine C-based equations (in
our population, prevalence of stage 3 CKD with the Levey
cystatin C-based equations (GFR = 76.7 × CC (mg/L) -
1.19) is as low as 1.1%, data not detailed). More studies are
urgently needed to confirm and explain these discrepan-
cies. Epidemiological population studies using GFR mea-
surements with a reference method are, once again,
urgently required.
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